FDA Approval of XPOVIO(TM) (selinexor) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

Press/Media

Period3 Jul 2019

Media coverage

1

Media coverage

  • TitleFDA Approval of XPOVIO(TM) (selinexor) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
    Media name/outletMarket News Publishing
    Country/TerritoryUnited States
    Date3/07/19
    PersonsSundar Jagannath